[{"orgOrder":0,"company":"LipoMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Promitil","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LipoMedix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LipoMedix \/ Not Applicable"},{"orgOrder":0,"company":"LipoMedix","sponsor":"ForDoz","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LipoMedix \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"LipoMedix \/ LipoMedix"},{"orgOrder":0,"company":"LipoMedix","sponsor":"ForDoz","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LipoMedix \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"LipoMedix \/ LipoMedix"}]

Find Clinical Drug Pipeline Developments & Deals by LipoMedix

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : LipoMedix's lead compound, Promitil® (PL-MLP), will be manufactured in the United States by ForDoz Pharma (ForDoz), specialty pharmaceutical company focused on the development, manufacturing, and commercialization of value-added sterile and complex inje...

                          Brand Name : Promitil

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 10, 2021

                          Lead Product(s) : Pegylated liposomal Mitomycin-c prodrug,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : ForDoz

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Fordoz will support LipoMedix to develop and manufacture Promitil in the United States. Promitil's unique liposomal formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemor...

                          Brand Name : Promitil

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 10, 2021

                          Lead Product(s) : Pegylated liposomal Mitomycin-c prodrug,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : ForDoz

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Study authors found that Promitil may be a useful agent in patients with metastatic colorectal cancer (CRC).

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 23, 2020

                          Lead Product(s) : Promitil,Capecitabine,Bevacizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank